Back to results
US 2024/0197730 A1Published application
Cancer treatment using parp inhibitors and plk1 inhibitors
AssigneeCardiff Oncology, Inc.
InventorsMaya RIDINGER, Mark ERLANDER
Life of this patent
Estimating the term…
Abstract
Provided include methods, compositions and kits for treating cancer in a subject. The method can comprise administrating a PARP inhibitor (for example, olaparib) and a PLK1 inhibitor (for example, onvansertib) to the subject in a manner sufficient to inhibit progression of the cancer.
Claims71
A method of treating cancer, the method comprising:
- administrating a Poly-(ADP-ribose) polymerase (PARP) inhibitor and a Polo-like kinase 1 (PLK1) inhibitor to a subject with cancer, thereby inhibiting progression of the cancer.
A method of sensitizing cancer cells to a PARP inhibitor, the method comprising:
- contacting cancer cells with a composition comprising a Polo-like kinase 1 (PLK1) inhibitor, thereby sensitizing the cancer cells to the PARP inhibitor.
A kit, comprising
- a Polo-like kinase 1 (PLK1) inhibitor;
- and
- a manual providing instructions for co-administrating the PLK1 inhibitor with a Poly-(ADP-ribose) polymerase (PARP) inhibitor to a subject for treating cancer.
Dependencies are inferred from the claim text.